Press Releases

Company to host investor conference call and webcast today at 5:00 pm EST GAITHERSBURG, Md. , Nov. 10, 2020 (GLOBE NEWSWIRE) -- Viela Bio  (Nasdaq:VIE), a biotechnology company dedicated to the discovery, development and commercialization of novel treatments for autoimmune and severe inflammatory

-- VIB7734 potently depleted   blood and   tissue resident plasmacytoid dendritic cells, an important source of inflammatory mediators in autoimmune diseases   -- -- Treatment with VIB7734 resulted in clinically significant reduction in CLASI-A , a clinical measure of cutaneous lupus lesions -- --

GAITHERSBURG, Md. , Nov. 02, 2020 (GLOBE NEWSWIRE) -- Viela Bio  (Nasdaq:VIE), a biotechnology company dedicated to the discovery, development and commercialization of novel treatments for autoimmune and severe inflammatory diseases, today announced it will host a webcast and conference call

GAITHERSBURG, Md. , Sept. 03, 2020 (GLOBE NEWSWIRE) -- Viela Bio (Nasdaq:VIE), a biotechnology company dedicated to the discovery, development and commercialization of novel treatments for autoimmune and severe inflammatory diseases, today announced that four abstracts have been accepted for

Company to host investor conference call and webcast today at 5:00 pm ET GAITHERSBURG, Md. , Aug. 12, 2020 (GLOBE NEWSWIRE) -- Viela Bio  (Nasdaq:VIE), a biotechnology company dedicated to the discovery, development and commercialization of novel treatments for autoimmune and severe inflammatory

GAITHERSBURG, Md. , Aug. 05, 2020 (GLOBE NEWSWIRE) -- Viela Bio (Nasdaq:VIE), a biotechnology company dedicated to the discovery, development and commercialization of novel treatments for autoimmune and severe inflammatory diseases, today announced it will host a webcast and conference call

UPLIZNA™ is the first and only B cell depleter approved for the treatment of NMOSD in adults who are anti-aquaporin-4 (AQP4) antibody positive GAITHERSBURG, Md. , June 11, 2020 (GLOBE NEWSWIRE) -- Viela Bio (Nasdaq:VIE) today announced that the U.S. Food and Drug Administration (FDA) has approved

GAITHERSBURG, Md., May 27, 2020 (GLOBE NEWSWIRE) -- Viela Bio, Inc. (Nasdaq: VIE ), a clinical-stage biotechnology company pioneering treatments for autoimmune and severe inflammatory diseases, today announced the pricing of an underwritten public offering of 3,600,000 shares of its common stock at

GAITHERSBURG, Md. , May 27, 2020 (GLOBE NEWSWIRE) -- Viela Bio, Inc. (Nasdaq:VIE), a clinical-stage biotechnology company pioneering treatments for autoimmune and severe inflammatory diseases, today announced the pricing of an underwritten public offering of 3,600,000 shares of its common stock at

GAITHERSBURG, Md. , May 26, 2020 (GLOBE NEWSWIRE) -- Viela Bio, Inc. (Nasdaq:VIE), a clinical-stage biotechnology company pioneering treatments for autoimmune and severe inflammatory diseases, today announced that it intends to offer and sell, subject to market and other conditions, 3,000,000